盈喜预告接连发布:BD成估值新锚,药企加速跨越生死线

21世纪经济报道
Feb 26

2月25日,先声药业发布盈喜预告。预告显示,2025财政年度公司预计录得收入约人民币77亿至78亿元,同比增长16.0%至17.6%;而归属于公司权益股东的利润更是有望达到人民币13亿至14亿元,同比增幅高达80.1%至93.9% 。  在医药行业整体仍在调整期中艰难跋涉的背景下,这份接近翻倍的利润增长答卷显得尤为耀眼。先声药业将增长归因于“创新药收入、对外授权许可收入以及投资组合公允价值净收益的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10